Trial of Pegasys® in Patients With Chronic Hepatitis C
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy and safety of Pegasys® 180μg for
subcutaneous (s.c.) injection in interferon (IFN)-treated or IFN-untreated chronic hepatitis
C patients except for those infected with genotype 1b of hepatitis C virus (HCV) and a high
viral load (≥ 100 KIU/mL).
In addition, this study will explore the efficacy and safety of Pegasys® 180μg for s.c.
injection given at 2 different periods between 24 and 48 weeks in IFN-untreated chronic
hepatitis C patients.